AARA Clinical Research - Murfreesboro Medical Clinic
Welcome,         Profile    Billing    Logout  
 1 Trial 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gibson, Christopher
TOGETHER-PsA, NCT06588296: Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight

Active, not recruiting
3
250
US
Ixekizumab, LY2439821, Tirzepatide, LY3298176
Eli Lilly and Company
Psoriatic Arthritis, Obesity
04/26
08/26
NCT05848258: An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis

Recruiting
2
380
Europe, US, RoW
LY3871801, Placebo
Eli Lilly and Company, Rigel Pharmaceuticals
Rheumatoid Arthritis
02/26
07/26
MEASURE, NCT05224661: Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events

Active, not recruiting
N/A
303
US
Prospective determination of the clinical utility of measurable residual disease (MRD) testing
Center for International Blood and Marrow Transplant Research, National Marrow Donor Program
Acute Myeloid Leukemia in Remission
07/29
07/29
Owen, Marcus
NCT06864026: A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)

Recruiting
4
200
US
Tirzepatide, LY3298176
Eli Lilly and Company
Psoriatic Arthritis, Overweight or Obesity
01/27
01/27
TOGETHER-PsA, NCT06588296: Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight

Active, not recruiting
3
250
US
Ixekizumab, LY2439821, Tirzepatide, LY3298176
Eli Lilly and Company
Psoriatic Arthritis, Obesity
04/26
08/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gibson, Christopher
TOGETHER-PsA, NCT06588296: Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight

Active, not recruiting
3
250
US
Ixekizumab, LY2439821, Tirzepatide, LY3298176
Eli Lilly and Company
Psoriatic Arthritis, Obesity
04/26
08/26
NCT05848258: An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis

Recruiting
2
380
Europe, US, RoW
LY3871801, Placebo
Eli Lilly and Company, Rigel Pharmaceuticals
Rheumatoid Arthritis
02/26
07/26
MEASURE, NCT05224661: Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events

Active, not recruiting
N/A
303
US
Prospective determination of the clinical utility of measurable residual disease (MRD) testing
Center for International Blood and Marrow Transplant Research, National Marrow Donor Program
Acute Myeloid Leukemia in Remission
07/29
07/29
Owen, Marcus
NCT06864026: A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)

Recruiting
4
200
US
Tirzepatide, LY3298176
Eli Lilly and Company
Psoriatic Arthritis, Overweight or Obesity
01/27
01/27
TOGETHER-PsA, NCT06588296: Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight

Active, not recruiting
3
250
US
Ixekizumab, LY2439821, Tirzepatide, LY3298176
Eli Lilly and Company
Psoriatic Arthritis, Obesity
04/26
08/26

Download Options